T cell receptors

1. A T cell receptor (TCR) that comprises a TCR alpha chain variable domain and a TCR beta chain variable domain, wherein:

(A) the TCR alpha chain variable domain is comprised in a sequence in which:

(i) amino acid residues 1-27 has (a) at least 90% identity to the sequence of amino acid residues 1-27 of SEQ ID No: 3 or (b) one, two or three amino acid insertions, deletions or substitutions relative to amino acid residues 1-27 of SEQ ID No: 3;

(ii) amino acid residues 28-33 is amino acid residues 28-33 of SEQ ID NO: 3;

(iii) amino acid residues 34-47 has (a) at least 90% identity to the sequence of amino acid residues 34-47 of SEQ ID NO: 3 or (b) one, two or three amino acid insertions, deletions or substitutions relative to amino acid residues 34-47 of SEQ ID No: 3;

(iv) amino acid residues 48-53 is amino acid residues 48-53 of any of SEQ ID NOs: 3 or 7;

(v) amino acid residues 54-90 has (a) at least 90% identity to the sequence of amino acid residues 54-90 of SEQ ID No: 3 or (b) one, two or three amino acid insertions, deletions or substitutions relative to amino acid residues 54-90 of SEQ ID No: 3; and

(vi) amino acid residues 91-105 is amino acid residues 91-105 of SEQ ID NO: 3; and

(B) the TCR beta chain variable domain is comprised in a sequence in which:

(i) amino acid residues 1-45 has (a) at least 90% identity to the amino acid sequence of residues 1-45 of SEQ ID No: 4 or (b) one, two or three amino acid insertions, deletions or substitutions relative to amino acid residues 1-45 of SEQ ID No: 4;

(ii) amino acid residues 46-50 is amino acid residues 46-50 of SEQ ID NO: 4;

(iii) amino acid residues 51-67 has (a) at least 90% identity to the sequence of amino acid residues 51-67 of SEQ ID NO: 4 or (b) one, two or three amino acid insertions, deletions or substitutions relative to amino acid residues 51-67 of SEQ ID No: 4;

(iv) amino acid residues 68-72 is amino acid residues 68-72 of SEQ ID NO: 4 or 11;

(v) amino acid residues 73-109 has (a) at least 90% identity to the sequence of amino acid residues 73-109 of SEQ ID NO: 4 or (b) one, two or three amino acid insertions, deletions or substitutions relative to amino acid residues 73-109 of SEQ ID No: 4; and

(vi) amino acid residues 110-123 is amino acid residues 110-123 of any one of SEQ ID NOs: 10, 11 or 12, or amino acid residues 110-123 of SEQ ID NO: 4 provided that amino acid residues 48-53 of the TCR alpha chain variable domain is amino acid residues 48-53 of SEQ ID NO: 7.

2. The TCR of claim 1 , wherein the TCR alpha chain variable domain is comprised in the amino acid sequence of SEQ ID NO: 3 or 7.

3. The TCR of claim 1 , wherein the TCR beta chain variable domain is comprised in the amino acid sequence of any one of SEQ ID NOs: 4, 10, 11 or 12.

4. The TCR of claim 1 , wherein the TCR alpha chain variable domain is comprised in the amino acid sequence of SEQ ID NO: 3 or 7, and the TCR beta chain variable domain is comprised in the amino acid sequence of any one of SEQ ID NOs: 4, 10, 11 or 12.

5. The TCR of claim 1 , wherein the TCR alpha chain variable domain is comprised in the amino acid sequence of SEQ ID NO: 7, and the TCR beta chain variable domain is comprised in the amino acid sequence of SEQ ID NO: 4.

6. The TCR of claim 1 , wherein the TCR alpha chain variable domain is comprised in the amino acid sequence of SEQ ID NO: 3, and the TCR beta chain variable domain is comprised in the amino acid sequence of SEQ ID NO: 10.

7. The TCR of claim 1 , wherein the TCR alpha chain variable domain is comprised in the amino acid sequence of SEQ ID NO: 3, and the TCR beta chain variable domain is comprised in the amino acid sequence of SEQ ID NO: 11.

8. The TCR of claim 1 , wherein the TCR alpha chain variable domain is comprised in the amino acid sequence of SEQ ID NO: 3, and the TCR beta chain variable domain is comprised in the amino acid sequence of SEQ ID NO: 12.

9. The TCR of claim 1 , which is an alpha-beta heterodimer, having an alpha chain TRAV10+TRAC constant domain sequence and a beta chain TRBV24-1+TRBC-2 constant domain sequence.

10. The TCR of claim 1 , which is in single chain format of the type Vα-L-Vβ, Vβ-L-Vα, Vα-Cα-L-Vβ, or Vα-L-Vβ-Cβ, wherein Vα and Vβ are TCR α and β variable regions respectively, Cα and Cβ are TCR α and β constant regions respectively, and L is a linker sequence.

11. One or more polynucleotides encoding the TCR of claim 1 .

12. A cell comprising the one or more polynucleotides of claim 11 .

13. A cell presenting the TCR of claim 1 , optionally wherein the cell is isolated or non-naturally occurring.

14. The cell of claim 13 , wherein the cell is a T-cell.

15. A method for treating cancer in a subject, comprising administering to the subject the T cell of claim 14 , wherein the subject has a cancer cell that expresses a melanoma-associated antigen (MAGE) A4 protein and/or a MAGE B2 protein.

16. A pharmaceutical composition comprising the cell of claim 13 , together with one or more pharmaceutically acceptable carriers or excipients.

17. An isolated or non-naturally occurring cell presenting a TCR encoded by a nucleic acid, wherein the nucleic acid encodes a TCR that comprises:

(A) a TCR alpha chain variable domain in which:

(i) amino acid residues 1-27 has (a) at least 90% identity to the sequence of amino acid residues 1-27 of SEQ ID No: 3 or (b) one, two or three amino acid insertions, deletions or substitutions relative to amino acid residues 1-27 of SEQ ID No: 3;

(ii) amino acid residues 28-33 is amino acid residues 28-33 of SEQ ID NO: 3;

(iii) amino acid residues 34-47 has (a) at least 90% identity to the sequence of amino acid residues 34-47 of SEQ ID NO: 3 or (b) one, two or three amino acid insertions, deletions or substitutions relative to amino acid residues 34-47 of SEQ ID No: 3;

(iv) amino acid residues 48-53 is amino acid residues 48-53 of any of SEQ ID NOs: 3 or 7;

(v) amino acid residues 54-90 has (a) at least 90% identity to the sequence of amino acid residues 54-90 of SEQ ID No: 3 or (b) one, two or three amino acid insertions, deletions or substitutions relative to amino acid residues 54-90 of SEQ ID No: 3; and

(vi) amino acid residues 91-105 is amino acid residues 91-105 of SEQ ID NO: 3; and

(B) the TCR beta chain variable domain is comprised in a sequence in which:

(i) amino acid residues 1-45 has (a) at least 90% identity to the amino acid sequence of residues 1-45 of SEQ ID No: 4 or (b) one, two or three amino acid insertions, deletions or substitutions relative to amino acid residues 1-45 of SEQ ID No: 4;

(ii) amino acid residues 46-50 is amino acid residues 46-50 of SEQ ID NO: 4;

(iii) amino acid residues 51-67 has (a) at least 90% identity to the sequence of amino acid residues 51-67 of SEQ ID NO: 4 or (b) one, two or three amino acid insertions, deletions or substitutions relative to amino acid residues 51-67 of SEQ ID No: 4;

(iv) amino acid residues 68-72 is amino acid residues 68-72 of SEQ ID NO: 4 or 11;

(v) amino acid residues 73-109 has (a) at least 90% identity to the sequence of amino acid residues 73-109 of SEQ ID NO: 4 or (b) one, two or three amino acid insertions, deletions or substitutions relative to amino acid residues 73-109 of SEQ ID No: 4; and

(vi) amino acid residues 110-123 is amino acid residues 110-123 of any one of SEQ ID NOs: 10, 11 or 12, or amino acid residues 110-123 of SEQ ID NO: 4, provided that amino acid residues 48-53 of the TCR alpha chain variable domain is amino acid residues 48-53 of SEQ ID NO: 7.

18. The cell of claim 17 , wherein the cell is a T-cell.

19. A method for treating cancer in a subject, comprising administering to the subject the T cell of claim 18 , wherein the subject has a cancer cell that expresses a melanoma-associated antigen (MAGE) A4 protein and/or a MAGE B2 protein.

20. A pharmaceutical composition comprising the cell of claim 17 , together with one or more pharmaceutically acceptable carriers or excipients.